“When they ask me is the glass half empty or half full [in regards to AIDS cure research], I say… we have a glass,” Carl Dieffenbach, PhD, told an audience at the 2012 International AIDS Conference in Washington on Sunday. Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious […]
Capitol Hill briefing highlights research agenda to end AIDS
The following is a guest blog post by Chris Collins, vice president and director of Public Policy at the Foundation for AIDS Research (amfAR) and Mitchell Warren, executive director of AVAC.
Looking back over three decades of AIDS, it’s hard to point to a better investment than research. Over the past three years, a string of HIV prevention research breakthroughs has put the ambitious goal of even talking about an end of AIDS within sight for the first time. With more strategic use of the tools we have today, we can bend the curve of new infections…
The National Institutes of Health (NIH)-funded HIV Vaccine Trials Network (HVTN) has started enrolling participants in a Phase 1 clinical trial to test a “second-generation” HIV vaccine candidate, meaning the vaccine is identical to the first generation candidate but it includes a special additive to enhance the vaccine response. The additive, or adjuvant, is granulocyte-macrophage […]
The following is a guest blog post by HIV Medicine Association Policy Officer, Kimberly Crump.
The U.S. Food and Drug Administration’s (FDA’s) 17-member Blood Products Advisory Committee voted unanimously to recommended FDA approval of OraSure Technologies’ over-the-counter, in-home HIV test Tuesday. After a full day of presentations…
A hodgepodge group of charities, green groups, trade unions, community organizations, celebrities, religious leaders and politicians are rallying this week to bring global attention to a Financial Transaction Tax (FTT) meant to “reform Main Street” with a small tax on bank profits. The idea is to implement a tax of less than half of one […]
The U.S. Food and Drug Administration (FDA) Antiviral Drugs Advisory Committee recommended Thursday that the supplemental application for Gilead Sciences’ HIV drug Truvada (a combination of emtricitabine plus tenofovir, or TDF-FTC) as pre-exposure prophylaxis (PrEP) be approved for high-risk, HIV-negative individuals to reduce the risk of sexually acquired HIV infection. The panel of medical experts, […]
The Global Fund to Fight AIDS, Tuberculosis and Malaria estimates an additional $1.6 billion in funding will be available in the 2012-2014 period, according to a press release issued Wednesday by the organization. “The new forecast is a result of strategic decisions made by the Board, freeing up funds that can be invested in countries […]
Despite fears that disproportionate resources devoted to HIV have crowded out other health services, global HIV/AIDS program funding does not subtract from other health issues, according to a study that appeared in the May edition of the American Journal of Tropical Medicine and Hygiene. Experts have disagreed over whether money injected into the global HIV/AIDS […]
The United Nations (UN) General Assembly gave some bad news Monday – the 2015 global HIV/AIDS targets will not be met unless there is significant scale up in several areas. The targets were set by the 2011 Political Declaration on HIV and AIDS: Intensifying our Efforts to Eliminate HIV and AIDS. The declaration was adopted […]
Stephen Lawn reminded the audience at the International Treatment as Prevention Workshop in Vancouver on Wednesday that antiretroviral therapy (ART) goes a long way to protect HIV-infected individuals from tuberculosis (TB). The HIV-associated TB epidemic requires “radical interventions,” according to Lawn. “DOTS [directly observed TB therapy, short course] just isn’t doing it.” He called the […]